Evidence map›Paper›PMID 38617518›Full record

ArticleTranslational cancer research2024

Linglong Tao, Xiaoyu Xu, Zhengxuying Fang, Petros Christopoulos, Diego Cortinovis, Yi Lu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Linglong Tao *Department of Radiation Oncology, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.
Xiaoyu Xu *Department of Radiation Oncology, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.
Zhengxuying FangDepartment of Radiation Oncology, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.
Petros ChristopoulosDepartment of Oncology, Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Heidelberg, Germany.
Diego CortinovisSC Medical Oncology/SS Lung Unit, Fondazione IRCCS San Gerardo dei Tintori Monza, Monza, Italy.
Yi LuDepartment of Radiation Oncology, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.ORCID https://orcid.org/0000-0002-2240-6824
Ningbo Medical Center Lihuili Hospital · CNNingbo University · CNAzienda Ospedaliera San Gerardo · ITGerman Center for Lung Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ras-related C3 botulinum toxin substrate 1 ( Methods: We analyzed data from various databases, including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project, cBioPortal, Tumor Immune Estimation Resource 2 (TIMER2), and published articles. A prognostic nomogram for liver hepatocellular carcinoma (LIHC) patients was developed based on RAC1-guanosine triphosphate (GTP) gene expression levels, which were validated using immunohistochemistry (IHC). Results: In this study, Conclusions: This extensive solid tumor analysis provides sound evidence that

Indexed as

immunotherapyliver hepatocellular carcinoma (LIHC)prognostic analysisRas-related C3 botulinum toxin substrate 1 (RAC1)solid tumors

Identifiers

PMID38617518
PMCPMC11009796
OpenAlexW4393265574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.